Dear Investors,
Brain therapies and neurological devices are becoming smaller, thinner, and more flexible, but precisely delivering these devices to their intended targets remains a significant challenge. Tissue dynamics can cause devices to bend, deflect, or miss their intended trajectory, potentially impacting precision and increasing tissue damage.
Join Opus8 for an exclusive investor meeting featuring Actuated Medical, a medical device company developing technologies for precision neurological procedures. Its lead platform, NeuralGlider®, uses controlled micro-motion to help thin probes and cannulas move through tissue with less buckling and deflection.
Company Overview
Actuated Medical is approaching a significant value-creation phase. With more than 10 years of development and $18M+ in non-dilutive funding behind its technology, the company is advancing NeuralGlider® toward human clinical translation and commercialization.
The platform has demonstrated compelling preclinical performance, including an 86.3% reduction in insertion force and a 72% reduction in flexible probe failures. NeuralGlider® is already used across 41+ research labs, with clinical programs advancing toward first-in-human studies.
Why Investors Are Taking Notice
Validated Technology — 10+ years of development, $18M+ in non-dilutive funding, and 15 issued patents.
Approaching Clinical Translation — First-in-human studies and FDA 510(k) milestones ahead.
Large Market Opportunity — $2.7B worldwide addressable market across 970,400 annual procedures.
Recurring Revenue Model — Single-use clinical devices priced at approximately $2,800 per procedure, with projected 89% gross margins.
Platform Expansion — Opportunities across DBS, SEEG, BCI, and CNS biologic and gene therapy delivery.
Multiple Strategic Pathways — OEM, licensing, co-development, and potential strategic acquisition opportunities.
